Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
Status:
Terminated
Trial end date:
2012-08-31
Target enrollment:
Participant gender:
Summary
The primary objective of this prospective, observational, post-marketing study is to evaluate
the patient characteristics, pre-treatment and treatment duration in Renal Cell Carcinoma
(RCC) patients who are candidates for systematic therapy and in whom a decision to treat with
Nexavar® has been made under real-life practice settings and approved reimbursement
restriction in Taiwan. Therefore, the main objective of the study is to collect data on:
Prescription pattern: to determine the factors affecting compliance and duration of treatment
with special attention given to education status, demography, disease details, pre-treatment,
concomitant medication and other baseline data
Nexavar® treatment and efficacy data
Adverse events using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0